Form 4 for IMMX Immix Biopharma, Inc.
Accepted 2024-05-20 00:00:00 ET · period of report 2024-05-20 · accession 0001493152-24-020778 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-20 | 2024-05-20 | IMMX | Rachman Ilya M | CEO, COB, Dir | A - Grant | — | +218.4K | 1.13M | +24% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-20 | A | A | 218,359 | — | 1,130,359 | D | — | — | (F1) Received in exchange for shares of common stock of Nexcella, Inc. which were held by the Reporting Person, which entity was merged with and into the Issuer on May 20, 2024, with the Issuer continuing as the surviving entity. |